Back to Agendas
BIOVACSAFE (IMI PROJECT)
Session Chair(s)
David J M Lewis, MD
Professor of Clinical Vaccine Immunology
Clinical Research Centre, University of Surrey, United Kingdom
BIOVACSAFE is a 30M€, 5 year Innovative Medicines Initiative project with 20 partners including industry (GSK, Sanofi Pasteur, Novartis Vaccines, deCODE), academia and SMEs. It integrates human clinical experimental medicine studies with animal models and large cohorts of adults and children to identify biomarkers associated with vaccine reactogenicity and immunosafety. A systems biology, bioinformatics and cross-species approach is pursued, together with careful clinical characterisation of adverse reactions following immunisation.
Speaker(s)
BIOVACSAFE: Translational Medicine and Systems Biology to Identify Biomarkers of Vaccine Reactogenicity
David J M Lewis, MD
Clinical Research Centre, University of Surrey, United Kingdom
Professor of Clinical Vaccine Immunology
Questing for Early Markers of Safety: A circular approach
Giuseppe Del Giudice
Novartis Vaccines, Italy
Global Head Translational Medicine
Have an account?